Regular ArticleImmunochemical Analysis of Vesicular Monoamine Transporter (VMAT2) Protein in Parkinson's Disease☆
References (54)
- et al.
Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase
Biochem. Biophys. Res. Commun.
(1984) - et al.
Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action
Neuron
(1997) - et al.
An immunohistochemical study of enkephalins and other neuropeptides in the striatum of the cat with evidence that the opiate peptides are arranged to form mosaic patterns in register with the striosomal compartments visible by acetylcholinesterase staining
Neuroscience
(1981) - et al.
Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transporters
Nucl. Med. Biol.
(1996) - et al.
Monoamine vesicular uptake sites in patients with Parkinson's disease and Alzheimer's disease, as measured by tritiated dihydrotetrabenazine autoradiography
Brain Res.
(1994) - et al.
A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter
Cell
(1992) - et al.
The organization of midbrain projections to the striatum in the primate: Sensorimotor-related striatum versus ventral striatum
Neurosci.
(1994) - et al.
Generation of transporter specific antibodies
Methods Enzymol.
(1998) - et al.
Energy-dependent uptake ofn
J. Biol. Chem.
(1986) - et al.
Dopamine transporter mRNA: Dense expression in ventral midbrain neurons
Mol. Brain Res.
(1992)
Single-step purification of polypeptides expressed inEscherichia coliS
Gene
Radioligand binding and immunoautoradiographic evidence for a lack of toxicity to dopaminergic terminals in human cocaine overdose victims
Brain Res.
A human synaptic vesicle monoamine transporter cDNA predicts post-translational modifications, reveals chromosome 10 gene localization and identifies Taq1 RFLPs
FEBS Lett.
Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: A postmortem study using tritiated tetrabenazine
Brain Res.
[3
Neuroscience
Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and hypersensitivity to cocaine and amphetamine
Neuron
Differential expression of tyrosine hydroxylase and membrane dopamine transporter genes in subpopulations of dopaminergic neurons of rat mesencephalon
Mol. Brain Res.
The dopamine transporter: Immunochemical characterization and localization in brain
J. Neurosci.
In vivo imaging of monoaminergic nerve terminals in normal and MPTP-lesioned primate brain using positron emission tomography (PET) and [11
Synapse
Neural degeneration and the transport of neurotransmitters
Ann. Neurol.
Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter
Proc. Natl. Acad. Sci. USA
Functional identification and molecular cloning of a human brain vesicle monoamine transporter
J. Neurochem.
Expression cloning of a reserpine-sensitive vesicular monoamine transporter
Proc. Natl. Acad. Sci. USA
Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging
Ann. Neurol.
Dopamine transporter is required for in vivo MPTP neurotoxicity: Evidence from mice lacking the transporter
J. Neurochem.
Cited by (168)
Neuromelanin: Its role in the pathogenesis of idiopathic Parkinson's disease and potential as a therapeutic target
2023, Parkinsonism and Related DisordersAutophagy as a gateway for the effects of methamphetamine: From neurotransmitter release and synaptic plasticity to psychiatric and neurodegenerative disorders
2021, Progress in NeurobiologyCitation Excerpt :METH impairs DAT activity either via direct inhibition or via reverting its direction, which potentiates the accumulation of freely diffusible DA in the extracellular space (Schmidt and Gibb, 1985; Sulzer, 2011; Sulzer and Rayport, 1990; Volz et al., 2007). Similar to what occurs in the animal and human METH-addicted brain, reduced DAT expression was detected in animal models and subjects with psychiatric disorders or PD (Wilson et al., 1996; Miller et al., 1999; Kitamura, 2009; McCann et al., 2008; McFadden et al., 2012; Markota et al., 2014; Purves-Tyson et al., 2017; Volkow and Morales, 2015; Chang et al., 2020). METH-induced impairment and downregulation of DAT lead to unusually high extracellular DA levels, which produces synaptic effects at both short and long-distance through a volume transmission (Fuxe et al., 2010).
Turmeric and Curcumin for Neurodegenerative Diseases
2021, Turmeric and Curcumin for Neurodegenerative Diseases
- ☆
J. Jankovic